Ask AI
ProCE Banner Activity

Optimizing Multidisciplinary Care in Extensive-Stage SCLC

Slideset

Downloadable slides on the current and evolving treatment paradigm in extensive-stage small-cell lung cancer (SCLC), optimal approaches for the selection of first-line therapy for individual patients (including veterans), novel and emerging targeted therapies, ways to navigate the selection of optimal treatment options for patients with relapsed extensive-stage SCLC, agents targeting DLL3 in neuroendocrine cancers, key agents and combinations under investigation in extensive-stage SCLC, safety and management of treatment-associated adverse events, key ongoing phase III trials in extensive-stage SCLC, and multidisciplinary strategies to support equitable care for all patients.

Released: September 15, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by educational grants from Amgen and Jazz Pharmaceuticals, Inc.

Amgen

Jazz Pharmaceuticals, Inc.

Target Audience

This activity is intended for oncologists, nurses, physician associates, pharmacists, and other healthcare professionals in VA and community oncology centers caring for patients with ES-SCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Analyze emerging evidence related to novel therapies and combination regimens in ES-SCLC

  • Formulate individualized treatment approaches for patients with ES-SCLC using current guidelines, approvals, clinical data, and patient-specific considerations

  • Design patient-centered care plans to prevent, recognize, and manage adverse events associated with current and emerging ES-SCLC treatments

  • Apply evidence-based strategies to promote equitable access, timely initiation of therapy, and supportive care for patients with ES-SCLC